A secondary analysis of the EMMY trial demonstrated that the very early administration of SGLT2Is following acute myocardial infarction does not exhibit adverse safety signals and appears equally effective in reducing NT-proBNP and improving functional and structural left ventricular markers [29]. This evidence concerns the gene NPPB and myocardial infarction.